TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06768489: A Phase 1b Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide for Multiple Myeloma, Newly Diagnosed AL Amyloidosis, and High-risk Smoldering Multiple Myeloma or in Combination With Pomalid

Sponsor: Janssen Research & Development, LLC · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 276 pts

Competing Trials Overlap

3 Active Trials

Excess Burn Exposure

$5,717,712

Rescue Site Savings

+$3,769,920

Unlock Full NCT06768489 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06768489 Rescue Dossier →